The Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration's Patient‐Reported Outcomes (PRO) working group has systematically reviewed and published consensus guidelines for QoL endpoints in NF1, NF2, and schwannomatosis trials. This evidence concerns the gene NF2 and neurofibromatosis.